US3507866A
(en)
|
1967-08-08 |
1970-04-21 |
Merck & Co Inc |
1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
|
US3567725A
(en)
|
1968-11-20 |
1971-03-02 |
Merck & Co Inc |
Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
|
US4294837A
(en)
|
1980-03-28 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
|
US4317909A
(en)
|
1980-03-24 |
1982-03-02 |
Sterling Drug Inc. |
Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
|
US4294836A
(en)
|
1980-03-24 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
|
US4309537A
(en)
|
1980-03-28 |
1982-01-05 |
Sterling Drug Inc. |
Production of imidazo[4,5-b]pyridin-2-ones or thiones
|
GB8709448D0
(en)
|
1987-04-21 |
1987-05-28 |
Pfizer Ltd |
Heterobicyclic quinoline derivatives
|
JPS63275582A
(ja)
|
1987-05-02 |
1988-11-14 |
Naade Kenkyusho:Kk |
2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法
|
DD262026A1
(de)
|
1987-07-10 |
1988-11-16 |
Akad Wissenschaften Ddr |
Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
|
FR2643903A1
(fr)
|
1989-03-03 |
1990-09-07 |
Union Pharma Scient Appl |
Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
|
US4963561A
(en)
|
1990-02-28 |
1990-10-16 |
Sterling Drug Inc. |
Imidazopyridines, their preparation and use
|
TW274550B
(es)
|
1992-09-26 |
1996-04-21 |
Hoechst Ag |
|
DE19601627A1
(de)
|
1996-01-18 |
1997-07-24 |
Bayer Ag |
Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
|
US6031105A
(en)
|
1996-04-09 |
2000-02-29 |
Pfizer Inc |
Substituted pyridines
|
ATE281834T1
(de)
|
1997-09-26 |
2004-11-15 |
Zentaris Gmbh |
Azabenzimidazol-verbindungen zur modulation der serin/threonin protein-kinase funktion
|
AU750564B2
(en)
|
1997-11-27 |
2002-07-25 |
Chugai Seiyaku Kabushiki Kaisha |
Examination method, examination reagent and remedy for diseases caused by variation in LKB1 gene
|
ZA9810490B
(en)
|
1997-12-03 |
1999-05-20 |
Dainippon Pharmaceutical Co |
2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
|
JP2003146987A
(ja)
|
1999-05-31 |
2003-05-21 |
Dainippon Pharmaceut Co Ltd |
2−アリールプリン−9−アセトアミド誘導体
|
AU4951300A
(en)
|
1999-05-31 |
2000-12-18 |
Chugai Research Institute For Molecular Medicine, Inc. |
Lkb1 gene knockout animals
|
JP3814125B2
(ja)
|
1999-06-02 |
2006-08-23 |
大日本住友製薬株式会社 |
2−アリール−8−オキソジヒドロプリン誘導体からなる医薬
|
JP2002100363A
(ja)
|
2000-09-25 |
2002-04-05 |
Mitsubishi Chemicals Corp |
リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
|
JP2002167387A
(ja)
|
2000-11-29 |
2002-06-11 |
Dainippon Pharmaceut Co Ltd |
2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体
|
US20050033048A1
(en)
|
2000-12-12 |
2005-02-10 |
Rajagopal Bakthavatchalam |
Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
IL160440A0
(en)
|
2001-09-04 |
2004-07-25 |
Boehringer Ingelheim Pharma |
Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
|
EP1438048A1
(en)
|
2001-10-18 |
2004-07-21 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
AU2003208415B2
(en)
|
2002-02-14 |
2009-05-28 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
TWI314928B
(en)
|
2002-02-28 |
2009-09-21 |
Novartis A |
5-phenylthiazole derivatives and use as pi3 kinase inhibitors
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
US20040063658A1
(en)
|
2002-05-06 |
2004-04-01 |
Roberts Christopher Don |
Nucleoside derivatives for treating hepatitis C virus infection
|
US20040204420A1
(en)
|
2002-08-05 |
2004-10-14 |
Rana Tariq M. |
Compounds for modulating RNA interference
|
WO2004041285A1
(en)
|
2002-10-31 |
2004-05-21 |
Amgen Inc. |
Antiinflammation agents
|
DK2316831T3
(da)
|
2002-11-21 |
2013-06-10 |
Novartis Ag |
2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
|
JP2006516561A
(ja)
|
2003-01-17 |
2006-07-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類
|
WO2004076454A1
(de)
|
2003-02-26 |
2004-09-10 |
Boehringer Ingelheim Pharma Gmbh & Co Kg |
Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
GB2400101A
(en)
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
AR044519A1
(es)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
CA2734052A1
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
EP1641423B1
(en)
|
2003-06-26 |
2010-03-17 |
Merck Sharp & Dohme Corp. |
Benzodiazepine cgrp receptor antagonists
|
EP1651673B1
(en)
|
2003-07-17 |
2008-04-16 |
University of Dundee |
Methods for use of an lkb1/strad/mo25 complex
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
US20080194019A1
(en)
|
2003-09-09 |
2008-08-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
|
EP1750715A1
(en)
|
2004-06-04 |
2007-02-14 |
Icos Corporation |
Methods for treating mast cell disorders
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
WO2006001266A1
(ja)
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
2-アリールプリン誘導体の製造方法
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
US7608622B2
(en)
|
2004-09-24 |
2009-10-27 |
Janssen Pharmaceutica Nv |
Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
CN101048410B
(zh)
|
2004-10-29 |
2010-06-23 |
泰博特克药品有限公司 |
抑制hiv的双环嘧啶衍生物
|
WO2006050076A1
(en)
|
2004-10-29 |
2006-05-11 |
Janssen Pharmaceutica, N.V. |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
SE0403006D0
(sv)
|
2004-12-09 |
2004-12-09 |
Biovitrum Ab |
New compounds
|
WO2006065703A1
(en)
|
2004-12-13 |
2006-06-22 |
Sunesis Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
|
SI1853588T1
(sl)
|
2005-02-16 |
2008-10-31 |
Astrazeneca Ab |
Kemične spojine
|
WO2006091737A1
(en)
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
EP1877388A2
(en)
|
2005-02-25 |
2008-01-16 |
Kudos Pharmaceuticals Ltd |
Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
|
JP2008531538A
(ja)
|
2005-02-25 |
2008-08-14 |
クドス ファーマシューティカルズ リミテッド |
2,4−ジアミノ−ピリドピリミジン誘導体とmTOR阻害剤としてのその使用
|
CA2603414C
(en)
|
2005-03-31 |
2012-09-18 |
Biomedics Inc. |
Anti-cd20 monoclonal antibody
|
RU2007140903A
(ru)
|
2005-04-05 |
2009-05-20 |
Фармакопия, Инк. (Us) |
Производные пурина и имидазопиридина для иммуносупрессии
|
ZA200710496B
(en)
|
2005-06-02 |
2009-04-29 |
Astrazeneca Ab |
Antibodies directed to CD20 and used thereof
|
US7989622B2
(en)
|
2005-10-07 |
2011-08-02 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
DK1940839T3
(da)
|
2005-10-07 |
2013-10-14 |
Exelixis Inc |
Pyridopyrimidione Inhibitors of P13Ka
|
CN102746298A
(zh)
|
2005-10-07 |
2012-10-24 |
埃克塞里艾克西斯公司 |
PI3Kα的吡啶并嘧啶酮抑制剂
|
CN101421625A
(zh)
|
2005-10-18 |
2009-04-29 |
乔治梅森知识产权公司 |
mTOR途径治疗诊断学
|
WO2007061737A2
(en)
|
2005-11-17 |
2007-05-31 |
Osi Pharmaceuticals, Inc. |
FUSED BICYCLIC mTOR INHIBITORS
|
EP1954699B1
(en)
|
2005-11-22 |
2012-09-19 |
Kudos Pharmaceuticals Ltd |
PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
GB0525083D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
AU2007204208A1
(en)
|
2006-01-11 |
2007-07-19 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives and their use in therapy
|
US20090281075A1
(en)
|
2006-02-17 |
2009-11-12 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
DK3421471T3
(da)
|
2006-04-25 |
2021-06-14 |
Astex Therapeutics Ltd |
Purin- og deazapurinderivater som farmaceutiske forbindelser
|
NZ572812A
(en)
|
2006-04-26 |
2010-09-30 |
Hoffmann La Roche |
THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
|
EP2016068A1
(en)
|
2006-05-03 |
2009-01-21 |
AstraZeneca AB |
Pyrazole derivatives and their use as pi3k inhibitors
|
CN101484452A
(zh)
|
2006-05-03 |
2009-07-15 |
阿斯利康(瑞典)有限公司 |
噻唑衍生物及其作为抗肿瘤药物的用途
|
EP2029593A1
(en)
|
2006-05-22 |
2009-03-04 |
AstraZeneca AB |
Indole derivatives
|
EP2995619B1
(en)
|
2006-08-02 |
2019-09-25 |
Cytokinetics, Inc. |
Certain chemical entities comprising imidazopyrimidines, compositions and methods
|
SI2057156T1
(sl)
|
2006-08-23 |
2017-06-30 |
Kudos Pharmaceuticals Limited |
Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
|
US20100144738A1
(en)
|
2006-09-05 |
2010-06-10 |
William Bornmann |
Inhibitors of c-met and uses thereof
|
AU2007338601C1
(en)
|
2006-09-05 |
2014-07-24 |
Emory University |
Tyrosine kinase inhibitors for prevention or treatment of infection
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
US20100022534A1
(en)
|
2006-09-14 |
2010-01-28 |
Astrazeneca |
2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
JP2010503649A
(ja)
|
2006-09-14 |
2010-02-04 |
アストラゼネカ アクチボラグ |
ピリミジン誘導体
|
WO2008032072A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
DK2066656T3
(da)
|
2006-09-26 |
2012-05-21 |
Celgene Corp |
5-substituerede quinazolinonderivater som antitumor-midler
|
CL2007002866A1
(es)
|
2006-10-04 |
2008-07-04 |
Pharmacopeia Inc |
Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
KR20140104060A
(ko)
|
2006-10-19 |
2014-08-27 |
시그날 파마소티칼 엘엘씨 |
헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
|
EP2078018B1
(en)
|
2006-10-19 |
2012-03-14 |
Signal Pharmaceuticals LLC |
Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
|
BRPI0719112A2
(pt)
|
2006-11-20 |
2013-12-10 |
Novartis Ag |
Sais e formas de cristal de 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-di-hidro-imi dazo[4,5-c]quinolin-1-il)-fenil]-propionitrila
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
BRPI0814503A2
(pt)
|
2007-07-09 |
2017-05-16 |
Astrazeneca Ab |
composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
|
WO2009007748A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
EA018708B1
(ru)
|
2007-07-09 |
2013-10-30 |
Астразенека Аб |
ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
|
PL2178916T3
(pl)
|
2007-07-31 |
2015-08-31 |
Regeneron Pharma |
Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
|
ES2449070T3
(es)
|
2007-09-05 |
2014-03-18 |
F. Hoffmann-La Roche Ag |
Terapia de combinación con anticuerpos anti-CD20 de tipo I y tipo II
|
CA2704710C
(en)
|
2007-09-26 |
2016-02-02 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
|
CN101883774A
(zh)
|
2007-10-16 |
2010-11-10 |
惠氏有限责任公司 |
噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
|
US8642660B2
(en)
|
2007-12-21 |
2014-02-04 |
The University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
EA201001017A1
(ru)
|
2008-01-15 |
2011-02-28 |
ВАЙЕТ ЭлЭлСи |
3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
|
US20110091574A1
(en)
|
2008-02-15 |
2011-04-21 |
Catholic Healthcare West |
Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor
|
CN102083800A
(zh)
|
2008-06-27 |
2011-06-01 |
阿维拉制药公司 |
杂芳基化合物和其用途
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
CN102271683B
(zh)
*
|
2008-11-13 |
2014-07-09 |
吉里德卡利斯托加公司 |
恶性血液病的治疗
|
CN102264743B
(zh)
|
2008-11-25 |
2015-02-11 |
罗彻斯特大学 |
Mlk抑制剂及其使用方法
|
WO2010137547A1
(ja)
|
2009-05-25 |
2010-12-02 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
ES2661850T3
(es)
|
2009-09-14 |
2018-04-04 |
Gilead Sciences, Inc. |
Moduladores de receptores del tipo toll
|
EP2493472B1
(en)
*
|
2009-10-26 |
2016-12-07 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
WO2011079118A1
(en)
|
2009-12-23 |
2011-06-30 |
Elan Pharmaceuticals, Inc |
Pteridinones as inhibitors of polo-like kinase
|
UA110697C2
(uk)
|
2010-02-03 |
2016-02-10 |
Сігнал Фармасьютікалз, Елелсі |
ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
|
JP2013522236A
(ja)
|
2010-03-12 |
2013-06-13 |
セルジーン コーポレイション |
レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー
|
US20110318336A1
(en)
|
2010-03-29 |
2011-12-29 |
George Mason Intellectual Properties, Inc. |
Identification and Treatment of Aggressive Lung Cancer Tumors
|
US20120028972A1
(en)
*
|
2010-07-30 |
2012-02-02 |
Lilly Wong |
Biomarker assays for detecting or measuring inhibition of tor kinase activity
|
KR20140019364A
(ko)
*
|
2011-03-11 |
2014-02-14 |
셀진 코포레이션 |
면역-관련 및 염증성 질환의 치료에 있어서의 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4h)-일)피페리딘-2-6-디온의 용도
|
AU2012290056B2
(en)
|
2011-08-03 |
2015-03-19 |
Signal Pharmaceuticals, Llc |
Identification of gene expression profile as a predictive biomarker for LKB1 status
|
CN107157990B
(zh)
*
|
2011-10-19 |
2020-01-07 |
西格诺药品有限公司 |
利用tor激酶抑制剂治疗癌症
|
AU2012304276B2
(en)
*
|
2011-12-02 |
2015-01-15 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
|
BR112014020786A2
(pt)
|
2012-02-24 |
2020-10-27 |
Signal Pharmaceuticals, Llc |
método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
|
KR102057358B1
(ko)
|
2012-03-15 |
2019-12-18 |
시그날 파마소티칼 엘엘씨 |
Tor 키나제 억제제를 사용한 암의 치료
|
EP2825171B1
(en)
|
2012-03-15 |
2018-03-14 |
Signal Pharmaceuticals, LLC |
Treatment of cancer with tor kinase inhibitors
|
BR112014022707A2
(pt)
|
2012-03-15 |
2020-10-27 |
Signal Pharmaceuticals, Llc |
uso de uma quantidade eficaz de um inibidor de quinase tor, método para melhorar os critérios de avaliação, método para a inibição da fosforilação, método para a inibição da atividade de proteína, método para a medição da inibição da fosforilação, kit
|
CN108992446A
(zh)
|
2012-03-15 |
2018-12-14 |
西格诺药品有限公司 |
用tor激酶抑制剂治疗癌症
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
MX2015014599A
(es)
|
2013-04-17 |
2016-03-03 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
|
CA2908830C
(en)
|
2013-04-17 |
2021-12-07 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
TWI674897B
(zh)
|
2013-04-17 |
2019-10-21 |
美商標誌製藥公司 |
藉二氫吡并吡化合物組合療法的癌症治療方法
|
WO2014172430A1
(en)
*
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
SG10201801965RA
(en)
|
2013-04-17 |
2018-04-27 |
Signal Pharm Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
WO2014172429A1
(en)
*
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
|
EA030726B1
(ru)
|
2013-04-17 |
2018-09-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
|
US20140314673A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|